Research progress on the anticancer mechanism of thalidomide and the function of its target protein CRBN
10.3969/j.issn.1001-1978.2015.06.002
- VernacularTitle:沙利度胺抗肿瘤机制及其作用靶点CRBN的研究进展
- Author:
Haining HUANG
;
Hao ZHANG
;
Hai WANG
- Publication Type:Journal Article
- Keywords:
thalidomide;
angiogenesis;
multiple myeloma;
CRBN;
immune modulation;
tumor therapeutics;
teratogenicity
- From:
Chinese Pharmacological Bulletin
2015;(6):745-748,749
- CountryChina
- Language:Chinese
-
Abstract:
Thalidomide and its analogues ( lenalidomide and po-malidomide) are small glutamic acid derivatives with strong im- ＜br> munomodulatory effects, belonging to immunomodulatory drug ( IMiD ) class . In addition , these thalidomide analogues demon- ＜br> strate an overlapping and diverse range of biological activities, including anti-angiogenesis and anti-teratogenicity. Importantly, the IMiDs exert anticancer effects such as inhibiting tumor cell proliferation and promoting tumor cell apoptosis and play impor-tant roles especially in clinical treatment of multiple myeloma. Recently, the screening and discovery of thalidomide binding protein, CRBN provides new clues to the research of its pharma-cological mechanisms and the develop ment of new generation of ＜br> thalidomide derivatives with less toxic side effects and more anti-tumor potency. This review briefly discusses the underlying mechanism of thalidomide and their derivatives’ action and their new identified target, as well as their contribution to the treat-ment of multiple myeloma.
